Essa Pharma Overview
- Founded
- 2009
- Status
- Public
- Employees
- 30
- Stock Symbol
- EPIX
- Investments
- 1
- Share Price
- $5.67
- (As of Wednesday Closing)
Essa Pharma General Information
Description
ESSA Pharma Inc is a pharmaceutical company. The company is in the preclinical stage, focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer. The company is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival.
Contact Information
Website
www.essapharma.com
Formerly Known As
ESSA Pharmaceuticals
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Primary Industry
Drug Discovery
Other Industries
Drug Delivery
Stock Exchange
NAS
Primary Office
- 999 West Broadway Street
- Suite 720
- Vancouver, British Columbia V5Z 1K5
- Canada
+1 (778) 000-0000
Essa Pharma Timeline
Essa Pharma Stock Performance
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $5.67 | $5.75 | $5.21 - $33.84 | $253M | 44.1M | 254K | -$0.86 |
Essa Pharma Financials Summary
|
In Thousands, USD |
TTM 31-Mar-2022 | FY 2021 30-Sep-2021 | FY 2020 30-Sep-2020 | FY 2019 30-Sep-2019 |
|---|---|---|---|---|
| EV | 83,121 | 149,930 | 161,249 | 63,823 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (37,836) | (36,943) | (23,565) | (12,142) |
| Net Income | (37,264) | (36,805) | (23,445) | (12,757) |
| Total Assets | 182,609 | 198,166 | 80,575 | 54,573 |
| Total Debt | 274 | 331 | 59 | 3,709 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Essa Pharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
This information is available in the PitchBook Platform. To explore Essa Pharma‘s full profile, request access.
Request a free trialEssa Pharma Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
ESSA Pharma Inc is a pharmaceutical company. The company is in the preclinical stage, focused on the development of smal
Drug Discovery
Vancouver, Canada
30
As of 2021
00000
000000000
00000
00000000
empor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitatio
0000 00000000
Cambridge, MA
00
As of 0000
00000
0000
0000-00-00
00000000
00000
00000
m dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore
0000000000000
Cambridge, MA
000
As of 0000
00000
000000&0
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialEssa Pharma Competitors (27)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Merrimack Pharmaceuticals | Formerly VC-backed | Cambridge, MA | 00 | 00000 | 00000000 | 00000 |
| 00000 | Formerly VC-backed | Cambridge, MA | 000 | 00000 | 000000&0 | |
| 00000 000000000 | Formerly VC-backed | Boulder, CO | 000 | 00000 | 000000&0 | 00000 |
| 0000000 | Formerly VC-backed | Austin, TX | 00 | 000.00 | 000000000 | 000.00 |
| 000000 00000000000 | Formerly VC-backed | South San Francisco, CA | 000 | 00000 | 00000000 | 00000 |
Essa Pharma Patents
Essa Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20210323931-A1 | Solid forms of an n-terminal domain androgen receptor inhibitor and uses thereof | Pending | 17-Apr-2020 | 0000000000 | |
| US-20210332016-A1 | Solid forms of an n-terminal domain androgen receptor inhibitor and uses thereof | Pending | 17-Apr-2020 | 0000000000 | |
| AU-2020248105-A1 | Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof | Pending | 28-Mar-2019 | 000000000 | |
| CA-3134545-A1 | Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof | Pending | 28-Mar-2019 | A61K45/06 |
Essa Pharma Executive Team (9)
Essa Pharma Board Members (13)
| Name | Representing | Role | Since |
|---|---|---|---|
| 0000 000000 | Self | Board Member | 000 0000 |
| 00000 000000000 00 | Essa Pharma | President, Chief Executive Officer & Board Member | 000 0000 |
| 00000000 000000 | Self | Board Member | 000 0000 |
| 0000 000000 | Self | Board Member | 000 0000 |
| 0000 000000 | Self | Board Member | 000 0000 |
Essa Pharma Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialEssa Pharma Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
This information is available in the PitchBook Platform. To explore Essa Pharma‘s full profile, request access.
Request a free trialEssa Pharma Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 00000 0000000 | 31-Jul-2019 | 0000000000 | 000.00 | Drug Discovery |
Essa Pharma Subsidiaries (1)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| 00000 000000000000 | Drug Discovery | Malvern, PA | 0000 |